{
    "nctId": "NCT00114296",
    "briefTitle": "Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer",
    "officialTitle": "A Pilot Study to Evaluate the Effects of Omega-3 Fatty Acids on Intermediate Markers of Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Breast density as measured by the Madena method at 1 year",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* At increased risk of developing breast cancer, as defined by 1 of the following criteria:\n\n  * 5-year Gail risk \u2265 1.7%\n  * Calculated 5-year Gail risk \u2265 5 times the average for age group, as defined by 1 of the following:\n\n    * At least 0.1% (for patients age 20-29)\n    * At least 1.0% (for patients age 30-39)\n    * At least 1.7% (for patients age 40 and over)\n  * Known BRCA1 or BRCA2 mutation carrier\n  * Family history consistent with hereditary breast cancer, as defined by any of the following:\n\n    * At least 4 relatives diagnosed with breast cancer at any age\n    * At least 2 first-degree relatives diagnosed with breast cancer at age 50 or younger\n    * Breast and ovarian cancer diagnosed in the same relative\n    * At least 2 occurrences of breast cancer and 1 occurrence of ovarian cancer at any age in the same family\n  * Atypical hyperplasia or lobular carcinoma in situ of the breast by prior biopsy\n  * History of unilateral ductal carcinoma in situ of the breast\n  * History of invasive stage I breast cancer in remission (completed local and systemic standard therapy)\n  * History of ovarian cancer in remission for \\> 5 years\n* Baseline mammogram performed within the past 6 months with an interpretation of not suspicious for malignancy (BIRAD 1-3)\n* Not eligible for OR refused standard breast cancer risk reduction strategies (e.g., prophylactic oophorectomy, prophylactic mastectomy, or tamoxifen)\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* SWOG 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute granulocyte count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 8.0 g/dL\n\nHepatic\n\n* SGOT and/or SGPT \u2264 2.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Bilirubin \u2264 2.0 times ULN\n\nRenal\n\n* Creatinine \u2264 2.0 mg/dL\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* No underlying medical, psychiatric, or social condition that would preclude study participation\n* No other invasive malignancy within the past 5 years except nonmelanoma skin cancer\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* More than 6 months since prior and no concurrent hormonal therapy, including any of the following:\n\n  * Antiestrogens\n  * Estrogen\n  * Selective estrogen-receptor modulators\n  * Progestins\n  * Aromatase inhibitors\n  * Hormonal contraceptives\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* No prior bilateral mastectomy\n\nOther\n\n* More than 3 months since prior and no concurrent chronic (i.e., \\> 3 times per week) non-steroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen, or indomethacin) or cyclooxygenase-2 inhibitors\n* No prior cancer treatment that would preclude study treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}